Treating Post-inflammatory hyperpigmentation with a tyrosinase-inhibitor
Agneta Troilius Rubin, MD, PhD, is an Associate Professor in Dermatology, Malmö, Sweden; Zoi...
Read MoreAgneta Troilius Rubin, MD, PhD, is an Associate Professor in Dermatology, Malmö, Sweden; Zoi...
Read MoreDr Jennifer David discusses the use of cysteamine 5% as a novel first line non‑hydroquinone...
Read MoreMukta Sachdev, MD, and Ninon Patrao, MD, review the current ingredients making waves in...
Read MoreCavallini Maurizio and Papagni Marco discuss the use of a home-based treatment to potentiate the benefits of a previous chemical peel procedure Hyperpigmentation can consist of localised dark spots caused...
Read MoreCase Study | 0
Leonardo Marini, MD, PhD, discusses two recent cases of treating melasma in female patients with a new 5% cysteamine topical formulation Afortunate woman craves nothing but a good anti‑depressant cream,...
Read MoreSabine Zenker provides a review of the treatment principles for melasma using bleaching topicals...
Read MoreScientis Pharma, a leading dermatology research company based in Geneva, Switzerland, has released the world’s first cysteamine-based cream to treat hyperpigmentation disorders. Cysteamine Cream® is a novel, super potent skin...
Read MoreMaurizio Ceccarelli examines how combination injections of hyaluronic and succinic acids can be used to treat hyperpigmentation and other skin changes caused by UV irradiation and photodamage Skin colour is...
Read More